These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 27363440

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
    Barnes PJ.
    J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of airway mucus hypersecretion.
    Rogers DF, Barnes PJ.
    Ann Med; 2006 Sep; 38(2):116-25. PubMed ID: 16581697
    [Abstract] [Full Text] [Related]

  • 7. Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models.
    Baker KE, Bonvini SJ, Donovan C, Foong RE, Han B, Jha A, Shaifta Y, Smit M, Johnson JR, Moir LM.
    Pulm Pharmacol Ther; 2014 Dec; 29(2):181-98. PubMed ID: 24929072
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
    Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, Dneprovskaia E, Noronha G, Soll R, Wrasidlo W, Acevedo LM, Cheresh DA.
    J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Progress in the development of kinase inhibitors for treating asthma and COPD.
    McClean N, Hasday JD, Shapiro P.
    Adv Pharmacol; 2023 Mar; 98():145-178. PubMed ID: 37524486
    [Abstract] [Full Text] [Related]

  • 13. Development of new drugs for COPD.
    Barnes PJ.
    Curr Med Chem; 2013 Mar; 20(12):1531-40. PubMed ID: 22963554
    [Abstract] [Full Text] [Related]

  • 14. Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies.
    Pelaia C, Vatrella A, Gallelli L, Lombardo N, Sciacqua A, Savino R, Pelaia G.
    Drug Des Devel Ther; 2021 Mar; 15():1275-1284. PubMed ID: 33790539
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.
    Onoue S, Misaka S, Kawabata Y, Yamada S.
    Expert Opin Drug Deliv; 2009 Aug; 6(8):793-811. PubMed ID: 19558334
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cytokine modulators as novel therapies for airway disease.
    Barnes PJ.
    Eur Respir J Suppl; 2001 Dec; 34():67s-77s. PubMed ID: 12392037
    [Abstract] [Full Text] [Related]

  • 20. Identifying Molecular Targets for New Drug Development for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?
    Barnes PJ.
    Semin Respir Crit Care Med; 2015 Aug; 36(4):508-22. PubMed ID: 26238638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.